Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan
Author:
Publisher
Springer Science and Business Media LLC
Subject
Hematology
Link
http://link.springer.com/content/pdf/10.1007/s12185-020-02828-7.pdf
Reference40 articles.
1. Gavriatopoulou M, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E. Anti-BCMA antibodies in the future management of multiple myeloma. Expert Rev Anticancer Ther. 2019;19:319–26.
2. Einsele H, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, et al. The anti-BCMA Bispecific T-cell Engager (BiTE®) molecule AMG 420 induced MRD negative complete responses in R/R multiple myeloma in a FIH study. In: 17th International Myeloma Workshop, abstract #OAB-025, Boston, USA. 2019.
3. Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci USA. 2019;116:9543–51.
4. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726–37.
5. Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, et al. CAR-T cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. Haematologica. 2019;104:2358–60.
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma;Annals of Hematology;2023-06-21
2. Advances in minimal residual disease monitoring in multiple myeloma;Critical Reviews in Clinical Laboratory Sciences;2023-05-26
3. Lumbar MR-based radiomics nomogram for detecting minimal residual disease in patients with multiple myeloma;European Radiology;2023-03-28
4. Novel immunotherapies in multiple myeloma;International Journal of Hematology;2022-05-18
5. Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: Current paradigm, guidelines, and future applications;International Journal of Laboratory Hematology;2021-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3